This report summarizes FDA’s performance results in meeting PDUFA goals and commitments for FY 2022 and FY 2023. Specifically, this report updates performance data for submissions received in FY 2022 (initially reported in the FY 2022 PDUFA performance report) and presents preliminary data on FDA’s progress in meeting FY 2023 goals. Updates on FDA’s accomplishments related to additional PDUFA VII commitments for FY 2023 and historical review trend data are also included
Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
Chicago
Food and Drug Administration, Health and Human Services Department.
"Performance Report to Congress: Prescription Drug User Fee Act FY 2023". Government.
Health and Human Services Department, Food and Drug Administration,
April 18, 2024.
https://www.govinfo.gov/app/details/CMR-HE20_4000-00195429
APA
Food and Drug Administration, Health and Human Services Department.
(2024, April 18).
Performance Report to Congress: Prescription Drug User Fee Act FY 2023.
[Government].
Health and Human Services Department, Food and Drug Administration.
https://www.govinfo.gov/app/details/CMR-HE20_4000-00195429
MLA
Food and Drug Administration, Health and Human Services Department.
Performance Report to Congress: Prescription Drug User Fee Act FY 2023.
Health and Human Services Department, Food and Drug Administration,
(18 Apr 2024),
https://www.govinfo.gov/app/details/CMR-HE20_4000-00195429
Bluebook
Food and Drug Administration, Health and Human Services Department, Performance Report to Congress: Prescription Drug User Fee Act FY 2023, GovInfo, (April 18, 2024),
https://www.govinfo.gov/app/details/CMR-HE20_4000-00195429
